Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
Lena Weiss(LMU Klinikum), Michael Haas(Harvard University), Michael von Bergwelt‐Baildon(German Cancer Research Center), Frank Gieseler(University Hospital Schleswig-Holstein), D. Quietzsch(Klinikum Chemnitz), Volker Heinemann(LMU Klinikum), Stefan Boeck(German Cancer Research Center), Anke Reinacher‐Schick(Ruhr University Bochum), Thomas Hoehler(Johannes Gutenberg University Mainz), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), C. Benedikt Westphalen(LMU Klinikum), Danmei Zhang(Ludwig-Maximilians-Universität München), Jens T. Siveke(German Cancer Research Center), Klara Dorman(LMU Klinikum), Laura Fischer(LMU Klinikum), Michael Schenk(Krankenhaus Barmherzige Brüder), G. Seipelt, Dirk Waldschmidt, Julia Mayerle(LMU Klinikum)
Cited by 2
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Cohort Profile: The Study of Health in Pomerania
|International Journal of Epidemiology|2010|1k